Blueprint Medicines Corp Stock
Price
Target price
€110.05
€110.05
-0.810%
-0.9
-0.810%
-
16:48 / Tradegate
WKN: A14SDD / Name: Blueprint / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Blueprint Medicines Corp Stock
Blueprint Medicines Corp shows a slight decrease today, losing -€0.900 (-0.810%) compared to yesterday.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Blueprint Medicines Corp stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Blueprint Medicines Corp in the next few years
Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Blueprint Medicines Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | -0.810% | -0.045% | 24.161% | 13.818% | 30.714% | 107.151% | 59.000% |
| Ironwood Pharmaceuticals | -2.460% | 5.172% | 27.615% | -89.107% | -85.476% | -94.082% | -93.146% |
| Arrowhead Pharmaceuticals Inc. | 1.050% | -1.325% | 0.676% | -43.797% | -27.494% | -58.745% | -63.698% |
| Novocure Ltd | 1.710% | -7.389% | -12.017% | -19.608% | -50.721% | -78.614% | -74.153% |
News
The Other AI Chipmaker: Why Marvell's Dip Is a Buy
[content-module:CompanyOverview|NASDAQ:MRVL]
In the race to power artificial intelligence (AI), some of the most essential players operate just outside the spotlight. Marvell Technology (NASDAQ:
Pegasystems: Mid-Cap GenAI Stock With Big Long-Term Potential
Among the companies that have reported earnings so far in the Q1 2025 cycle, Pegasystems (NASDAQ: PEGA) is one that stands out. The AI stock popped by nearly 29% after its earnings release.
The
Blueprint Medicines Stock: Executives Sell Shares Amid Growth
Blueprint Medicines, a biopharmaceutical company headquartered in Cambridge, Massachusetts, recently reported several significant stock transactions by its leadership team. Multiple executives sold
